retatrutide phase 2 nejm weight loss 48 weeks triple agonist TRIUMPH-1 Trial Results: for Obesity Retatrutide vs. Tirzepatide: The Next-Gen

Visit us at mybeewell.com to learn more about our programs and start your consultation today.

This enhanced GCG receptor activity, combined with the effects of GIP receptor engagement, is believed to contribute to the superior weight loss observed with this triple agonist

Read More Related Podcasts In this weeks special Be HEALTHistic Ask the Doctors Video Extra, Drs

Health systems and clinicians should evaluate how these changes affect patient demand, prescribing patterns, and care coordination, while remaining alert to further guidance from CMS and the FDA as demonstration models unfold.

Use this to your advantage while traveling

Gallo, MD, FAAD Desmond Shipp, MD, MSBS, FAAD Last updated: 2/17/26